Evidence map›Paper›PMID 26639105›Full record

ArticleJournal of cellular physiology2016

E11/Podoplanin Protein Stabilization Through Inhibition of the Proteasome Promotes Osteocyte Differentiation in Murine in Vitro Models.

Katherine A Staines, Matt Prideaux, Steve Allen, David J Buttle, Andrew A Pitsillides, Colin Farquharson

Open access · hybridAbstract read
In one paragraph

Article in Journal of cellular physiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. AnJBMR plus · 2021
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Katherine A StainesRoslin Institute and R(D)SVS, The University of Edinburgh, Easter Bush, Midlothian, United Kingdom.
Matt PrideauxThe University of Adelaide, North Terrace, Adelaide, Australia.
Steve AllenRoyal Veterinary College, Royal College Street, London, United Kingdom.
David J ButtleDepartment of Infection and Immunity, The University of Sheffield Medical School, Beech Hill Road, Sheffield, United Kingdom.
Andrew A PitsillidesRoyal Veterinary College, Royal College Street, London, United Kingdom.
Colin FarquharsonRoslin Institute and R(D)SVS, The University of Edinburgh, Easter Bush, Midlothian, United Kingdom.
Royal Veterinary College · GBRoslin Institute · GBUniversity of Adelaide · AUUniversity of Edinburgh · GBUniversity of Sheffield · GB

Funding

Arthritis Research UK 20413Arthritis Research UK 20581Biotechnology and Biological Sciences Research Council BB/J004316/1Medical Research Council G0900740Medical Research Council MR/K001744/1Versus Arthritis 20413
6 · The paper itself

Abstract

The transmembrane glycoprotein E11 is considered critical in early osteoblast-osteocyte transitions (osteocytogenesis), however its function and regulatory mechanisms are still unknown. Using the late osteoblast MLO-A5 cell line we reveal increased E11 protein/mRNA expression (P < 0.001) concomitant with extensive osteocyte dendrite formation and matrix mineralization (P < 0.001). Transfection with E11 significantly increased mRNA levels (P < 0.001), but immunoblotting failed to detect any correlative increases in E11 protein levels, suggestive of post-translational degradation. We found that exogenous treatment of MLO-A5 and osteocytic IDG-SW3 cells with 10 μM ALLN (calpain and proteasome inhibitor) stabilized E11 protein levels and induced a profound increase in osteocytic dendrite formation (P < 0.001). Treatment with other calpain inhibitors failed to promote similar osteocytogenic changes, suggesting that these effects of ALLN rely upon its proteasome inhibitor actions. Accordingly we found that proteasome-selective inhibitors (MG132/lactacystin/ Bortezomib/Withaferin-A) produced similar dose-dependent increases in E11 protein levels in MLO-A5 and primary osteoblast cells. This proteasomal targeting was confirmed by immunoprecipitation of ubiquitinylated proteins, which included E11, and by increased levels of ubiquitinylated E11 protein upon addition of the proteasome inhibitors MG132/Bortezomib. Activation of RhoA, the small GTPase, was found to be increased concomitant with the peak in E11 levels and its downstream signaling was also observed to promote MLO-A5 cell dendrite formation. Our data indicate that a mechanism reliant upon blockade of proteasome-mediated E11 destabilization contributes to osteocytogenesis and that this may involve downstream targeting of RhoA. This work adds to our mechanistic understanding of the factors regulating bone homeostasis, which may lead to future therapeutic approaches.

Indexed as

AnimalsCalpainCell DifferentiationCell LineCysteine Proteinase InhibitorsDose-Response Relationship, DrugMembrane GlycoproteinsMice, Inbred C57BLOsteoblastsOsteocytesPhenotypePodoplaninProteasome Endopeptidase ComplexProteasome InhibitorsProtein StabilityProteolysisCalpainCysteine Proteinase InhibitorsMembrane GlycoproteinsPdpn protein, mousePodoplaninProteasome Endopeptidase ComplexProteasome InhibitorsrhoA GTP-Binding ProteinRhoA protein, mouserho GTP-Binding ProteinsRNA, Messenger

Identifiers

PMID26639105
PMCPMC4832367
OpenAlexW2195422332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.